📈 Jumpstart Signal Watchlist — September 24, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.96 is 8% below 3yr high $14.14 · ⏳ SMA200 $7.08 (current price $12.96 is above) · 💰 Market Cap $731M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA50 (10.8%)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×1; showing 3 of 4).
✅ Paysign Targets $117M Revenue as Patient-Affordability Business Surges — Yahoo Finance.
🤖 Paysign highlighted strong growth in its patient-affordability business and reiterated raised 2026 guidance, including revenue of $114 million to $117 million and adjusted EBITDA of $35 million to $38 million. That outlook is supportive for the stock because it signals continued expansion and improving profitability.
✅ Paysign at 17th Annual Midwest IDEAS Conference: growth broadens — Investing.com.
🤖 At the conference, Paysign said its plasma payments unit remains a leader while patient-affordability revenue is accelerating, with first-half 2026 revenue up more than 85% year over year. The company also restated its full-year revenue and EBITDA guidance, which reinforces a constructive growth story.
⚪️ Paysign: Growth In Both Segments, But Guidance Implies Lower H2 ... — Seeking Alpha.
🤖 This article is more of an analysis piece than a fresh company catalyst. It acknowledges strong quarterly growth and raised guidance, but argues valuation and second-half earnings expectations may limit further upside, making the net implication mixed.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Grindr Inc. operates a location-based social networking and dating platform primarily serving gay, bisexual, transgender, queer, and other LGBTQ+ adults. Its mobile app enables users to discover, connect, chat, and share content with nearby or global users, with features offered through free and subscription tiers.
- 🎯 Current $15.87 is 36% below 3yr high $24.73 · ⏳ SMA200 $13.56 (current price $15.87 is above) · 💰 Market Cap $2.8B
- GRND shows decent technicals supported by positive sentiment.

💎 Quality (Q): 39/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 25% (>20%); Revenue growth 33% (>15%); PEG ratio 1.27 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×1).
✅ Full Transcript: Grindr Q2 2026 Earnings Call - Grindr (NYSE:GRND) — Benzinga.
🤖 Grindr reported 33% year-over-year revenue growth to $138 million and raised full-year guidance to about $540 million in revenue and $232 million in adjusted EBITDA. That combination of strong operating performance and improved outlook is positive for the stock.
✅ Grindr at Goldman Sachs Communacopia + Technology Conference 2026: ai drives growth — Investing.com.
🤖 The company said it is growing users and revenue while leaning harder on AI, and management highlighted plans for an AI-powered premium tier called EDGE. The strategic update and growth commentary are constructive for investor sentiment.
⚪️ Grindr: Downgrade To Hold; AI-Native Pivot And EDGE Promise Balanced By Valuation — Seeking Alpha.
🤖 This article acknowledges promising AI initiatives and the EDGE launch plan, but argues the stock already reflects much of the upside and downgrades the shares to Hold. The piece is mixed rather than clearly bullish or bearish.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $57.95 is 2% below 3yr high $59.13 · ⏳ SMA200 $48.44 (current price $57.95 is above) · 💰 Market Cap $14.4B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×2 ❌×1 ⚪️×2).
✅ Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B — Yahoo Finance.
🤖 Exelixis is preparing a potential zanzalintinib launch after positive STELLAR-303 results and continues to target substantial CABOMETYX sales. The company also remains active in seeking oncology business-development opportunities.
✅ Exelixis Announces Update on Patent Litigation Trial — Business Wire.
🤖 The Federal Circuit upheld the validity of three patents covering cabozantinib, helping preserve CABOMETYX market exclusivity. The decision supports revenue protection by indicating the earliest potential generic launch would be January 15, 2030, subject to further proceedings.
❌ Exelixis at Wells Fargo conference: zanzalintinib takes center stage — Investing.com.
🤖 Management retained confidence in zanzalintinib and CABOMETYX's long-term potential, but trimmed near-term CABOMETYX guidance because neuroendocrine-tumor patient movement has been slower than expected. That guidance reduction is a negative near-term catalyst.
⚪️ Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Hold" by Brokerages — MarketBeat.
🤖 Analysts maintain an overall Hold consensus, with an average price target of $50.29. The rating mix indicates limited consensus for a strong near-term directional move.
⚪️ Exelixis at Citigroup summit: building a second growth engine — Investing.com.
🤖 Management highlighted CABOMETYX market-share gains and the long-term opportunity for zanzalintinib, but also acknowledged development risk from a frontline kidney-cancer setback. The balanced growth prospects and risks make the near-term stock impact mixed.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 At/above 3yr high $79.06 (current $79.06) · ⏳ SMA200 $53.99 (current price $79.06 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.9%)
- 🔔 Strong above EMA50 (12.0%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ Red Violet (NASDAQ:RDVT) Upgraded at Zacks Research — MarketBeat.
🤖 Zacks Research upgraded Red Violet from hold to strong buy. The article also cited quarterly EPS and revenue that exceeded analyst expectations, supporting a positive view of the stock.
✅ Red Violet (RDVT) Expands FOREWARN Reach Through This Latest Partnership — Yahoo Finance.
🤖 Red Violet’s FOREWARN subsidiary partnered with the Pacific West Association of REALTORS to provide identity-verification and safety services to more than 10,000 members. The expanded distribution and customer reach are positive catalysts.
❌ Red Violet (NASDAQ:RDVT) Stock Rating Lowered by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded Red Violet from buy to hold, creating a negative analyst-rating signal. However, the broader analyst consensus remained moderately bullish and the company’s recent results exceeded expectations.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Worthington Enterprises designs and manufactures building and consumer products, including HVAC and water systems, metal roofing and ceiling components, tools, portable propane and helium cylinders, outdoor-living products, and celebration supplies. Its brands include Bernzomatic, Balloon Time, Coleman propane cylinders, Garden Weasel, and LEVEL5 Tools.
- 🎯 Current $60.33 is 10% below 3yr high $67.39 · ⏳ SMA200 $55.26 (current price $60.33 is above) · 💰 Market Cap $2.9B
- WOR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 978% (>20%); ROE 15% (>15%); Low LT D/E 0.30 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Worthington Enterprises Reports First Quarter Fiscal 2027 Results — GlobeNewswire.
🤖 Worthington reported fiscal Q1 2027 adjusted EPS of $0.82 and revenue of $343.9 million, both above expectations. The company also highlighted higher earnings, EBITDA, and cash flow, which is a constructive signal for the stock.
✅ Worthington Q1 FY27 slides: data center push drives earnings beat — Investing.com.
🤖 This article says Worthington beat estimates on both revenue and adjusted EPS, and notes the stock jumped in after-hours trading. The strong quarter and favorable market reaction are positive for WOR.
✅ Worthington (NYSE:WOR) Delivers Strong Q3 CY2026 Results — Yahoo Finance.
🤖 Worthington posted revenue and adjusted EPS ahead of Wall Street expectations, with double-digit year-over-year sales growth. Beating consensus on both top and bottom lines is typically supportive for the share price.
🍭 Bonus (B): 0/10 — Steel Works & Blast Furnaces

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 At/above 3yr high $63.52 (current $63.52) · ⏳ SMA200 $35.47 (current price $63.52 is above) · 💰 Market Cap $84.4B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.08 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.6%)
- 🔔 Strong above EMA50 (17.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ HPE's Networking Orders Signal Continued Growth: What's Ahead? — Zacks.
🤖 HPE reported 74.9% reported networking revenue growth and 36% growth in normalized networking orders, with Networks for AI orders reaching $700 million in the quarter. The article also cites a gigawatt-scale Oracle deal and raised AI-networking targets, supporting growth expectations.
✅ Here's Why Hewlett Packard Enterprise (HPE) is a Strong Value Stock — Zacks.
🤖 Zacks assigned HPE a #2 Buy rank and noted that eight analysts raised fiscal-2026 earnings estimates during the prior 60 days. The consensus EPS estimate increased by $0.40 to $3.81, indicating improving earnings expectations.
✅ Hewlett Packard Enterprise (NYSE:HPE) Receives Average Rating of "Moderate Buy" from Brokerages — MarketBeat.
🤖 The brokerage consensus was Moderate Buy, with 13 of 19 analysts assigning buy or strong-buy ratings and an average 12-month price target of $69.18. This reflects broadly constructive analyst sentiment toward HPE.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: Digi International Inc. (DGII) is an Industrial Internet of Things (IIoT) technology company that provides cellular routers, gateways, embedded system-on-modules (SOMs), single-board computers (SBCs), RF modules, and sensor-based solutions for connecting devices in demanding environments.
- 🎯 Current $76.75 is 10% below 3yr high $85.24 · ⏳ SMA200 $58.69 (current price $76.75 is above) · 💰 Market Cap $2.9B
- DGII shows decent technicals supported by positive sentiment.

💎 Quality (Q): 46/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 48% (>20%); Low LT D/E 0.16 (<1.0); PEG ratio 1.27 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (5.4%)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ SmartSense Report: 79% of Loss and Organized Retail Crime Prevention Leaders More Concerned About Cargo Theft Than Ever Before — Business Wire.
🤖 SmartSense by Digi released survey findings highlighting increased concern about cargo theft and the need for prevention technologies. The report supports demand for Digi’s IoT-based monitoring and security solutions, although it does not provide new financial guidance.
✅ Digi International Inc. (DGII) Given Average Rating of "Moderate Buy" by Analysts — MarketBeat.
🤖 Analysts maintained a Moderate Buy consensus, with five Buy ratings and two Holds and an average price target of $82.40. The article also cited quarterly EPS and revenue that exceeded expectations and 29% year-over-year revenue growth.
✅ Digi International CEO Ron Konezny Discusses 29% YoY Revenue Beat Last Quarter — Yahoo Finance.
🤖 Digi’s CEO discussed the company’s 29% year-over-year revenue beat for the prior quarter. The earnings outperformance provides a favorable fundamental catalyst for DGII.
🍭 Bonus (B): 10/10 — Computer Communications Equipment (Technology sector)